USPH

Business Context and Reporting Period

Company: U.S. Physical Therapy, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: The Company operates outpatient physical and occupational therapy clinics providing preventive and post-operative care. As of March 31, 2010, the Company operated 367 clinics in 43 states. The business model primarily involves subsidiary clinic partnerships where the Company holds a majority interest, alongside wholly-owned facilities and management contracts for third-party clinics.

Key Financial Metrics

Key Operational Metrics:

• Total Patient Visits: 468,651 (Q1 2010) vs. 462,958 (Q1 2009).
• Net Patient Revenue per Visit: $104.08 (Q1 2010) vs. $100.80 (Q1 2009).
• Clinic Operating Costs as % of Net Revenues: 75.3% (Q1 2010) vs. 75.4% (Q1 2009).

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 4.6% year-over-year, driven by a 3.2% increase in revenue per visit and a 1.2% increase in total patient visits. New clinics opened or acquired in the prior year contributed significantly to visit growth.
• Profitability: Net income attributable to common shareholders rose 15.2% to $3.2 million. Operating income increased slightly to $6.7 million.
• Acquisitions and Divestitures:
  • Acquisitions: Acquired a 70% interest in five clinics for $9.0 million (cash and seller notes) in February 2010 and one practice for $100,000 in March 2010. Goodwill increased by $11.6 million.
  • Divestitures: Sold a 51% interest in five Texas clinics in March 2010, recording a pre-tax gain of $578,000.
• Liquidity and Debt: Cash balances increased 78.4% from the prior year-end ($6.4M to $11.5M). The Company significantly increased borrowings on its revolving credit facility from $0.4 million to $10.9 million to fund acquisitions and working capital.
• Bad Debt Provision: The provision for doubtful accounts increased to $1.0 million (2.1% of net patient revenues) from $0.7 million (1.5%) in the prior year.

Guidance, Outlook, and Risks

Management Commentary: Management believes cash flow from operations and the revolving credit facility are sufficient to fund working capital, clinic development, and future acquisitions through at least March 2011. The Company plans to continue opening new clinics and evaluating acquisition opportunities. No specific financial guidance for the full year was provided in this filing.

Risks and Contingencies:

• Reimbursement Dependence: Approximately 80% of revenue comes from third-party payors (managed care, commercial insurers, workers' comp) and 20% from Medicare/Medicaid. Changes in reimbursement rates or caps could materially impact profitability.
• Medicare Cap: The Company is subject to the Medicare therapy cap ($1,860 for 2010). While the Patient Protection and Affordable Care Act extended the exception process through 2010, the cap may still result in lost revenues.
• Economic Conditions: High unemployment rates and uncertain economic conditions may adversely affect patient volume and ability to collect receivables.
• Regulatory Environment: Operations are subject to extensive federal and state regulations, including potential changes from healthcare reform legislation.

Investor Verification Checklist

• Acquisition Integration: Verify the performance of the five clinics acquired in February 2010 and the impact of the $11.6 million goodwill addition on future impairment testing.
• Receivables Quality: Monitor the trend in the provision for doubtful accounts (increased to 2.1% of revenue) and days sales outstanding (46 days) to assess collection efficiency.
• Debt Covenants: Confirm continued compliance with the Credit Agreement covenants, specifically the consolidated leverage ratio requirement (must be less than 1.0 to 1.0) given the increased revolver usage.
• Medicare Cap Exposure: Assess the volume of services provided to Medicare patients near the $1,860 cap and the success rate of exception claims under the new Affordable Care Act provisions.
• Noncontrolling Interests: Review the $2.0 million net income attributable to noncontrolling interests and the $2.2 million distributions paid to partners, as this reduces cash available to common shareholders.